Alcon, Inc.'s Treatment of Glaucoma and Ocular Hypertension, TRAVATANZ(TM) Solution, Approved in Japan

FORT WORTH, Texas--(BUSINESS WIRE)--Alcon, Inc. (NYSE: ACL) announced today that the Ministry of Health, Labor and Welfare in Japan has approved TRAVATANZ™ (travoprost ophthalmic solution) 0.004% for the treatment of glaucoma and ocular hypertension. TRAVATANZ™ solution is the first prostaglandin analogue that is free of benzalkonium chloride (BAC), a commonly used preservative in topical ocular medications. Research suggests that chronic use of ophthalmic solutions containing BAC could negatively affect the ocular surface. Because glaucoma and ocular hypertension are chronic ocular conditions requiring daily treatment, Alcon developed TRAVATANZ™ as a BAC-free version of its glaucoma therapy, TRAVATAN® solution. TRAVATANZ™ has the same enduring efficacy as original TRAVATAN® which is marketed around the world. TRAVATANZ™ was approved as TRAVATAN Z® in the United States in 2006.

MORE ON THIS TOPIC